Literature DB >> 27236050

ALS: A bucket of genes, environment, metabolism and unknown ingredients.

Mónica Zufiría1, Francisco Javier Gil-Bea2, Roberto Fernández-Torrón3, Juan José Poza3, Jose Luis Muñoz-Blanco4, Ricard Rojas-García5, Javier Riancho6, Adolfo López de Munain7.   

Abstract

The scientific scenario of amyotrophic lateral sclerosis (ALS) has dramatically changed since TDP-43 aggregates were discovered in 2006 as the main component of the neuronal inclusions seen in the disease, and more recently, when the implication of C9ORF72 expansion in familial and sporadic cases of ALS and frontotemporal dementia was confirmed. These discoveries have enlarged an extense list of genes implicated in different cellular processes such as RNA processing or autophagia among others and have broaden the putative molecular targets of the disease. Some of ALS-related genes such as TARDBP or SOD1 among others have important roles in the regulation of glucose and fatty acids metabolism, so that an impairment of fatty acids (FA) consumption and ketogenic deficits during exercise in ALS patients would connect the physiopathology with some of the more intriguing epidemiological traits of the disease. The current understanding of ALS as part of a continuum with other neurodegenerative diseases and a crossroads between genetic, neurometabolic and environmental factors represent a fascinating model of interaction that could be translated to other neurodegenerative diseases. In this review we summarize the most relevant data obtained in the ten last years and the key lines for future research in ALS.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Environmental factors; Genetics; Metabolism; Neurodegeneration; Toxins

Mesh:

Year:  2016        PMID: 27236050     DOI: 10.1016/j.pneurobio.2016.05.004

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  50 in total

Review 1.  Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis.

Authors:  Peter W French; Russell Ludowyke; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2018-12-05       Impact factor: 3.911

2.  Dysregulation of TDP-43 intracellular localization and early onset ALS are associated with a TARDBP S375G variant.

Authors:  Kathy Newell; Francesca Paron; Miguel Mompean; Jill Murrell; Elisa Salis; Cristiana Stuani; Gary Pattee; Maurizio Romano; Douglas Laurents; Bernardino Ghetti; Emanuele Buratti
Journal:  Brain Pathol       Date:  2018-12-27       Impact factor: 6.508

Review 3.  Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration.

Authors:  David Castanedo-Vazquez; Pilar Bosque-Varela; Arancha Sainz-Pelayo; Javier Riancho
Journal:  J Neurol       Date:  2018-05-29       Impact factor: 4.849

4.  Neuroprotective Effects of Testosterone in Male Wobbler Mouse, a Model of Amyotrophic Lateral Sclerosis.

Authors:  Agustina Lara; Iván Esperante; Maria Meyer; Philippe Liere; Noelia Di Giorgio; Michael Schumacher; Rachida Guennoun; Gisella Gargiulo-Monachelli; Alejandro Federico De Nicola; Maria Claudia Gonzalez Deniselle
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

5.  GNE missense mutation in recessive familial amyotrophic lateral sclerosis.

Authors:  Çiğdem Köroğlu; Rezzak Yılmaz; Mine Hayriye Sorgun; Seyhun Solakoğlu; Özden Şener
Journal:  Neurogenetics       Date:  2017-10-31       Impact factor: 2.660

6.  Reduced retinal nerve fiber layer (RNFL) thickness in ALS patients: a window to disease progression.

Authors:  Mohammad Rohani; Alipasha Meysamie; Babak Zamani; Mohammad Mahdi Sowlat; Fahimeh Haji Akhoundi
Journal:  J Neurol       Date:  2018-04-30       Impact factor: 4.849

7.  Studies of Environmental Risk Factors in Amyotrophic Lateral Sclerosis (ALS) and a Phase I Clinical Trial of L-Serine.

Authors:  Walter G Bradley; R X Miller; T D Levine; E W Stommel; P A Cox
Journal:  Neurotox Res       Date:  2017-05-19       Impact factor: 3.911

Review 8.  Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.

Authors:  Ranjeet Prasad Dash; R Jayachandra Babu; Nuggehally R Srinivas
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

9.  S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD.

Authors:  Elaine Pirie; Chang-Ki Oh; Xu Zhang; Xuemei Han; Piotr Cieplak; Henry R Scott; Amanda K Deal; Swagata Ghatak; Fernando J Martinez; Gene W Yeo; John R Yates; Tomohiro Nakamura; Stuart A Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

Review 10.  High content analysis in amyotrophic lateral sclerosis.

Authors:  Federica Rinaldi; Dario Motti; Laura Ferraiuolo; Brian K Kaspar
Journal:  Mol Cell Neurosci       Date:  2016-12-11       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.